EMUC15 - Resource Centre - Search Results

Resource Centre Back to Resource Centre

429 results (Loading...)

Video Filters×
  • organe

  • access

  • procedure

  • pathology

178 Abstracts

  • Introduction & Objectives1. Compare the recurrence and progression-free survival  among patients treated and untreated with post-TUR chemotherapy. 2. Determine the target population with NMIBC potentially beneficiary of MMC post-TUR.Material & MethodsNon experimental longitudinal prospective study of 349 consecutive patients with NMIBC subsidiary of MMC post-TUR in the Jerez Hospital between 2010-2013. Potential predictors of efficacy of MMC post-TUR in our series were analysed: Age, gender, smoking quit at the time of diagnosis, early recurrence.ResultsThe average rate of patients included in the program is 53.9%, an increase of 79.3% (p <0.001) at 3 years.  Mean follow-up 26.3 ± 0.7 months. Mean time to first recurrence significantly higher in the MMC post-TUR group receiving [43.5 months (95% CI, 40.7 to 46.3) vs 38.5 months (95% CI, 35.5 to 41.6); p <0.05].  The absolute risk reduction of recurrence with MMC post-TUR is 14.5% (95% CI, 5.9 to 23.5%, p <0.001), and the number of patients needed to be treated (NNT) of 6.9 (95% CI, 4.3 to 17.9 P <0.001).  The statistical analysis of the exposed cohort to MMC post-TUR (n = 164) and unexposed (n = 185) results that the MMC post-TUR is effective in reducing the risk of recurrence in tumours PTa-1, low-high grade, single-multiple, ≤ 3cm maximum diameter, with no history of bladder tumours in the 12 months prior, with a sample of muscle layer in the TUR, and  without pretreatment with MMC.ConclusionsMMC decreases the percentage of tumour recurrence in NMIBC, and increases disease-free time. The MMC increases disease-free time in all prognosis recurrence groups. The effectiveness of MMC post-TUR in our country is similar to that reported by other groups. Our findings suggest a potential benefit of MMC post-TUR in all patients with primary NMIBC or without early relapse, ≤ 3cm without prior treatment with intravesical MMC. Baena Villamarín C.1, Beardo Villar P.2, Pérez Pérez A.B.2, Castro Dorantes M.J.2, Gamaza Martínez R.2, Gavira Moreno R.3 7th European Multidisciplinary Meeting on Urological Cancers 1Complejo Hospitalario Llerena-Zafra, Dept. of Urology, Badajoz, 2Hospital De Jerez De La Frontera, Dept. of Urology, Cádiz, 3Hospital De Jerez De La Frontera, Dept. of Pharmacy, Cádiz 58749 EMUC15-0239 P126
  • Introduction & Objectives1. Compare the recurrence and progression-free survival  among patients treated and untreated with post-TUR chemotherapy. 2. Determine the target population with NMIBC potentially beneficiary of MMC post-TUR.Material & MethodsNon experimental longitudinal prospective study of 349 consecutive patients with NMIBC subsidiary of MMC post-TUR in the Jerez Hospital between 2010-2013. Potential predictors of efficacy of MMC post-TUR in our series were analysed: Age, gender, smoking quit at the time of diagnosis, early recurrence.ResultsThe average rate of patients included in the program is 53.9%, an increase of 79.3% (p <0.001) at 3 years.  Mean follow-up 26.3 ± 0.7 months. Mean time to first recurrence significantly higher in the MMC post-TUR group receiving [43.5 months (95% CI, 40.7 to 46.3) vs 38.5 months (95% CI, 35.5 to 41.6); p <0.05].  The absolute risk reduction of recurrence with MMC post-TUR is 14.5% (95% CI, 5.9 to 23.5%, p <0.001), and the number of patients needed to be treated (NNT) of 6.9 (95% CI, 4.3 to 17.9 P <0.001).  The statistical analysis of the exposed cohort to MMC post-TUR (n = 164) and unexposed (n = 185) results that the MMC post-TUR is effective in reducing the risk of recurrence in tumours PTa-1, low-high grade, single-multiple, ≤ 3cm maximum diameter, with no history of bladder tumours in the 12 months prior, with a sample of muscle layer in the TUR, and  without pretreatment with MMC.ConclusionsMMC decreases the percentage of tumour recurrence in NMIBC, and increases disease-free time. The MMC increases disease-free time in all prognosis recurrence groups. The effectiveness of MMC post-TUR in our country is similar to that reported by other groups. Our findings suggest a potential benefit of MMC post-TUR in all patients with primary NMIBC or without early relapse, ≤ 3cm without prior treatment with intravesical MMC. Baena Villamarín C.1, Beardo Villar P.2, Pérez Pérez A.B.2, Castro Dorantes M.J.2, Gamaza Martínez R.2, Gavira Moreno R.3 7th European Multidisciplinary Meeting on Urological Cancers 1Complejo Hospitalario Llerena-Zafra, Dept. of Urology, Badajoz, 2Hospital De Jerez De La Frontera, Dept. of Urology, Cádiz, 3Hospital De Jerez De La Frontera, Dept. of Pharmacy, Cádiz 58749 EMUC15-0239 P126
  • Introduction & Objectives1. Compare the recurrence and progression-free survival  among patients treated and untreated with post-TUR chemotherapy. 2. Determine the target population with NMIBC potentially beneficiary of MMC post-TUR.Material & MethodsNon experimental longitudinal prospective study of 349 consecutive patients with NMIBC subsidiary of MMC post-TUR in the Jerez Hospital between 2010-2013. Potential predictors of efficacy of MMC post-TUR in our series were analysed: Age, gender, smoking quit at the time of diagnosis, early recurrence.ResultsThe average rate of patients included in the program is 53.9%, an increase of 79.3% (p <0.001) at 3 years.  Mean follow-up 26.3 ± 0.7 months. Mean time to first recurrence significantly higher in the MMC post-TUR group receiving [43.5 months (95% CI, 40.7 to 46.3) vs 38.5 months (95% CI, 35.5 to 41.6); p <0.05].  The absolute risk reduction of recurrence with MMC post-TUR is 14.5% (95% CI, 5.9 to 23.5%, p <0.001), and the number of patients needed to be treated (NNT) of 6.9 (95% CI, 4.3 to 17.9 P <0.001).  The statistical analysis of the exposed cohort to MMC post-TUR (n = 164) and unexposed (n = 185) results that the MMC post-TUR is effective in reducing the risk of recurrence in tumours PTa-1, low-high grade, single-multiple, ≤ 3cm maximum diameter, with no history of bladder tumours in the 12 months prior, with a sample of muscle layer in the TUR, and  without pretreatment with MMC.ConclusionsMMC decreases the percentage of tumour recurrence in NMIBC, and increases disease-free time. The MMC increases disease-free time in all prognosis recurrence groups. The effectiveness of MMC post-TUR in our country is similar to that reported by other groups. Our findings suggest a potential benefit of MMC post-TUR in all patients with primary NMIBC or without early relapse, ≤ 3cm without prior treatment with intravesical MMC. Baena Villamarín C.1, Beardo Villar P.2, Pérez Pérez A.B.2, Castro Dorantes M.J.2, Gamaza Martínez R.2, Gavira Moreno R.3 7th European Multidisciplinary Meeting on Urological Cancers 1Complejo Hospitalario Llerena-Zafra, Dept. of Urology, Badajoz, 2Hospital De Jerez De La Frontera, Dept. of Urology, Cádiz, 3Hospital De Jerez De La Frontera, Dept. of Pharmacy, Cádiz 58749 EMUC15-0239 P126
  • Introduction & Objectives1. Compare the recurrence and progression-free survival  among patients treated and untreated with post-TUR chemotherapy. 2. Determine the target population with NMIBC potentially beneficiary of MMC post-TUR.Material & MethodsNon experimental longitudinal prospective study of 349 consecutive patients with NMIBC subsidiary of MMC post-TUR in the Jerez Hospital between 2010-2013. Potential predictors of efficacy of MMC post-TUR in our series were analysed: Age, gender, smoking quit at the time of diagnosis, early recurrence.ResultsThe average rate of patients included in the program is 53.9%, an increase of 79.3% (p <0.001) at 3 years.  Mean follow-up 26.3 ± 0.7 months. Mean time to first recurrence significantly higher in the MMC post-TUR group receiving [43.5 months (95% CI, 40.7 to 46.3) vs 38.5 months (95% CI, 35.5 to 41.6); p <0.05].  The absolute risk reduction of recurrence with MMC post-TUR is 14.5% (95% CI, 5.9 to 23.5%, p <0.001), and the number of patients needed to be treated (NNT) of 6.9 (95% CI, 4.3 to 17.9 P <0.001).  The statistical analysis of the exposed cohort to MMC post-TUR (n = 164) and unexposed (n = 185) results that the MMC post-TUR is effective in reducing the risk of recurrence in tumours PTa-1, low-high grade, single-multiple, ≤ 3cm maximum diameter, with no history of bladder tumours in the 12 months prior, with a sample of muscle layer in the TUR, and  without pretreatment with MMC.ConclusionsMMC decreases the percentage of tumour recurrence in NMIBC, and increases disease-free time. The MMC increases disease-free time in all prognosis recurrence groups. The effectiveness of MMC post-TUR in our country is similar to that reported by other groups. Our findings suggest a potential benefit of MMC post-TUR in all patients with primary NMIBC or without early relapse, ≤ 3cm without prior treatment with intravesical MMC. Baena Villamarín C.1, Beardo Villar P.2, Pérez Pérez A.B.2, Castro Dorantes M.J.2, Gamaza Martínez R.2, Gavira Moreno R.3 7th European Multidisciplinary Meeting on Urological Cancers 1Complejo Hospitalario Llerena-Zafra, Dept. of Urology, Badajoz, 2Hospital De Jerez De La Frontera, Dept. of Urology, Cádiz, 3Hospital De Jerez De La Frontera, Dept. of Pharmacy, Cádiz 58749 EMUC15-0239 P126
  • Introduction & Objectives1. Compare the recurrence and progression-free survival  among patients treated and untreated with post-TUR chemotherapy. 2. Determine the target population with NMIBC potentially beneficiary of MMC post-TUR.Material & MethodsNon experimental longitudinal prospective study of 349 consecutive patients with NMIBC subsidiary of MMC post-TUR in the Jerez Hospital between 2010-2013. Potential predictors of efficacy of MMC post-TUR in our series were analysed: Age, gender, smoking quit at the time of diagnosis, early recurrence.ResultsThe average rate of patients included in the program is 53.9%, an increase of 79.3% (p <0.001) at 3 years.  Mean follow-up 26.3 ± 0.7 months. Mean time to first recurrence significantly higher in the MMC post-TUR group receiving [43.5 months (95% CI, 40.7 to 46.3) vs 38.5 months (95% CI, 35.5 to 41.6); p <0.05].  The absolute risk reduction of recurrence with MMC post-TUR is 14.5% (95% CI, 5.9 to 23.5%, p <0.001), and the number of patients needed to be treated (NNT) of 6.9 (95% CI, 4.3 to 17.9 P <0.001).  The statistical analysis of the exposed cohort to MMC post-TUR (n = 164) and unexposed (n = 185) results that the MMC post-TUR is effective in reducing the risk of recurrence in tumours PTa-1, low-high grade, single-multiple, ≤ 3cm maximum diameter, with no history of bladder tumours in the 12 months prior, with a sample of muscle layer in the TUR, and  without pretreatment with MMC.ConclusionsMMC decreases the percentage of tumour recurrence in NMIBC, and increases disease-free time. The MMC increases disease-free time in all prognosis recurrence groups. The effectiveness of MMC post-TUR in our country is similar to that reported by other groups. Our findings suggest a potential benefit of MMC post-TUR in all patients with primary NMIBC or without early relapse, ≤ 3cm without prior treatment with intravesical MMC. Baena Villamarín C.1, Beardo Villar P.2, Pérez Pérez A.B.2, Castro Dorantes M.J.2, Gamaza Martínez R.2, Gavira Moreno R.3 7th European Multidisciplinary Meeting on Urological Cancers 1Complejo Hospitalario Llerena-Zafra, Dept. of Urology, Badajoz, 2Hospital De Jerez De La Frontera, Dept. of Urology, Cádiz, 3Hospital De Jerez De La Frontera, Dept. of Pharmacy, Cádiz 58749 EMUC15-0239 P126
×